Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pharmacogenomics in clinical care

Wysocki, Kenneth PhD, FNP, FAANP (Nurse Practitioner Clinician)1; Seibert, Diane PhD, APRN, FAANP, FAAN (Associate Dean for Academic Affairs)2

Section Editor(s): Wysocki, Kenneth PhD, FNP, FAANP; Seibert, Diane PhD, APRN, FAANP, FAAN

Journal of the American Association of Nurse Practitioners: August 2019 - Volume 31 - Issue 8 - p 443–446
doi: 10.1097/JXX.0000000000000254
Unraveling the Genome
Buy

ABSTRACT Health care designed specifically for a person based on their genetic makeup (“personalized” or “precision” medicine) is expanding rapidly, especially in the area of drug selection. Pharmacogenomic (PGx) testing, when drugs and doses are selected based on an individual's genetic profile, is increasingly being used to guide the selection of drugs or therapies to optimize outcomes and minimize side effects. Based on an individual's genetic blueprint, health care providers now have important information about how a drug is likely to behave in that individual's body. Pharmacogenomic information on drug labels is now available for nearly 250 drugs. Health care organizations are also increasingly making this information available to customers to reduce emergency department visits, improve outcomes (selecting the right chemotherapy doses), and reduce cost. This study reviews some of the challenges and benefits on using PGx testing to improve clinical outcomes.

1Optum /United Healthcare Housecalls, Tempe, Arizona,

2Daniel K Inouye Graduate School of Nursing, Uniformed Services University, Bethesda, Maryland

Competing interests: The authors report no conflicts of interest.

Received April 29, 2019

Received in revised form May 08, 2019

Accepted May 14, 2019

© 2019 American Association of Nurse Practitioners
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website